Advancing Maternal Health and Highlights from the CAMT Annual Meeting
On October 23, the Coalition to Advance Maternal Therapeutics (CAMT) convened its annual all-member meeting. This gathering brought together experts, advocates, and stakeholders dedicated to enhancing maternal health through improved therapeutic research and regulatory frameworks. The meeting featured special presentations by Dr. Camille Fabiyi from the National Institute of Child Health and Human Development (NICHD)…
Continue Reading Advancing Maternal Health and Highlights from the CAMT Annual Meeting
Supporting Pregnant and Lactating Populations in Health Care
Despite there being more than 3.5 million births in the United States each year, pregnant and lactating populations have been underrepresented in research, leading to limited data in the pregnancy section of drugs approved by the U.S. Food and Drug Administration (FDA) and to women, their families, and health care providers often needing to make…
Continue Reading Supporting Pregnant and Lactating Populations in Health Care
July All-Member Meeting Focuses on 2025 Appropriations, Policy Comments
By: Leah Golbert, SWHR Communications Intern On July 25, 2024, members of the Coalition to Advance Maternal Therapeutics (CAMT) convened to discuss updates on advancements in the inclusion of pregnant and lactating populations in clinical research. CAMT advocated for several federal appropriations requests for FY2024 and FY2025, which were the focus of updates during the…
Continue Reading July All-Member Meeting Focuses on 2025 Appropriations, Policy Comments
CAMT All-Member Meeting Sheds Light on Industry’s Work to Supporting Pregnant and Lactating Populations in Research
By: Stacey Friedman, Center Road Solutions The Coalition to Advance Maternal Therapeutics (CAMT) hosted its annual all-member meeting on October 23, 2023 in Washington, D.C. The meeting brought together CAMT’s membership of advocates, policy professionals, and other stakeholders spanning diverse organizations, all of whom are dedicated to improving access to medication for pregnant and lactating…
Federal Agency Representations Note Progress, Outstanding Work on Including Pregnant and Lactating Populations in Research
During the recent national webinar and congressional briefing, “PRGLAC Then and Now: Where We Are and Where We’re Going,” the last of a three-part congressional briefing series hosted by the Coalition to Advance Maternal Therapeutics (CAMT), invited representatives from key federal agencies to discuss how they were working to advance recommendations of the Task Force…
Excluding Pregnant and Lactating Populations from Research Leaves Them Behind, Panelists Agree
Experts agree that leaving pregnant and lactating populations out of clinical trials can cause harm and create uncertainty for both mother and baby. During the national webinar and congressional briefing, “Pregnant and Lactating Populations in Research: How Leaving These Populations Out Leaves Them Behind,” part two of a three-part series hosted by the Coalition to…
CAMT Works to Advance Inclusion of Pregnant and Lactating Populations in Research in Last Stretch of 117th Congress
While Congress and the Administration had several priorities toward the end of the 117th Congress, including passing an end-of-year spending package for fiscal year 2023, the Coalition to Advance Maternal Therapeutics (CAMT) was successful in its efforts to help drive policy toward greater inclusion of pregnant and lactating populations in research. Fiscal Year 2023 Omnibus…
CAMT Congressional Briefing Series Kicks Off with Experts Discussing Considerations Surrounding Inclusion of Pregnant and Lactating Populations in Research
Including pregnant and lactating populations in research is critical to gaining a greater understanding of the safety and efficacy of medications on these populations and improve outcomes for both mother and baby. However, women of childbearing age have historically been excluded from clinical trials. In 1977, as a result of certain drugs (namely thalidomide) causing…
Reps. Castor, Fitzpatrick, and Underwood Introduce Legislation to Promote Greater Inclusion of Pregnant and Lactating Women in Research
Representatives Castor, Fitzpatrick, and Underwood on December 13, 2022 introduced H.R. 9487, the Advancing Safe Medications for Moms and Babies Act of 2022.
NICHD’s Role in Advancing Research on Pregnant and Lactating Populations
Dr. Dianchi Bianchi, Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, addressed members of the Coalition to Advance Maternal Therapeutics during an October 2022 meeting about NICHD’s role in advancing research on pregnant and lactating populations.
Continue Reading NICHD’s Role in Advancing Research on Pregnant and Lactating Populations